Zuventus Healthcare Limited has issued a formal clarification to counter what it described as false and misleading communications circulating in the market regarding its future, including rumours of closure or rebranding.
The company categorically denied any reports of shutdown, suspension, or transfer of its business assets. It said operations are continuing normally, with its field staff functioning at full strength across the country. The clarification comes amid growing concern among stakeholders following the spread of unverified information through informal channels.
Zuventus also addressed claims linking it to Zorvia Healthcare Limited, stating that it has no association or affiliation with any such entity. The company termed these claims inaccurate and misleading, warning that misinformation of this nature can damage business confidence and stakeholder trust.
Founded in 2002, Zuventus Healthcare is a subsidiary of Emcure Pharmaceuticals, which is listed on the Bombay Stock Exchange and the National Stock Exchange. The company reiterated its commitment to developing, manufacturing, and marketing high-quality and affordable medicines, a core pillar of its business strategy.
Zuventus said it is actively pursuing appropriate legal remedies to protect its goodwill and the interests of its stakeholders. From a business perspective, the move signals an effort to safeguard brand value and maintain operational stability in a competitive pharmaceutical market.
The company has a strong presence in branded generics, with a diversified portfolio addressing chronic and acute conditions across cardiology, diabetology, gastroenterology, orthopaedics, pain management, and nutraceuticals. Supported by robust manufacturing standards, a growing field force, and a patient-centric approach, Zuventus said it remains focused on sustaining growth while strengthening long-term relationships with doctors, partners, and patients across India.
